Marathon Leaves PhRMA Citing Closure Of Deal On Controversial DMD Drug

April 21, 2017 at 2:42 PM
Marathon Pharmaceuticals announced Thursday (April 20) that it is resigning from all of its trade association memberships, including the Pharmaceutical Research and Manufacturers of America, following closure of a deal to sell its its Duchenne muscular dystrophy drug, Emflaza, which the company was accused of price gouging earlier this year. While Marathon's resignation letter, obtained by Inside Health Policy , cites the closure of the deal as the reason for leaving PhRMA, a drug pricing lobby group frequently critical of...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.